Clinical Trial

A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
A phase 1/2 dose escalation / dose expansion study of Enzomenib (DSP-5336) in patients with acute leukemia.
Protocol Amendment History 16 amendments
This ClinicalTrials.gov record has been amended 16 times since 2021-07-26; most recent amendment 2026-03-20.
Status change: Not Yet Recruiting → Recruiting 2022-03-04
Trial Details
NCT Number NCT04988555
Lead Sponsor Sumitomo Pharma America, Inc.
Conditions Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Acute, Multiple Myeloma, Myelodysplastic Syndromes
Enrollment 606 participants
Start Date 2022-02-28
Primary Completion 2027-06-30 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-03-24